Autoimmunity against endogenous vasoactive neuropeptides (VIP, PACAP, CGRP) is proposed as a pathogenic mechanism for MS and ALS, with evidence of anti-neuropeptide antibodies in these patients.
Key findingAutoimmune attack on endogenous vasoactive neuropeptides (VIP, PACAP, CGRP) is proposed as a pathogenic mechanism for MS and ALS, with detection of an
What the researchers found
Autoimmune attack on endogenous vasoactive neuropeptides (VIP, PACAP, CGRP) is proposed as a pathogenic mechanism for MS and ALS, with detection of anti-neuropeptide antibodies and correlation with disease activity — neuropeptide autoimmunity as neurodegeneration cause.
Why it matters
Relevant for neuropeptides, neuroprotection, immune-function.
How the study worked
review study.
What this study cannot tell us
See abstract.
How to read the evidence
preliminary evidence.
When this study was published
Published in 2008.
The bigger picture
Advances peptide research.
Questions still open
- Further research needed.
- Clinical translation to evaluate.
Common questions
What was studied?
What was found?
Read the original research
Are multiple sclerosis and amyotrophic lateral sclerosis autoimmune disorders of endogenous vasoactive neuropeptides?
Medical hypotheses, 70(2), 413-8
Citation
Staines, Donald R. (2008). Are multiple sclerosis and amyotrophic lateral sclerosis autoimmune disorders of endogenous vasoactive neuropeptides?. Medical hypotheses, 70(2), 413-8.